The hemophilia A market has a new date for the diary: Feb. 28. Officials at the FDA put the date on the agenda at Sanofi and Sobi by accepting the partners’ hemophilia A drug candidate efanesoctocog alfa for priority review.

Arch Venture Partners is bankrolling a biotech that could render high-throughput screening obsolete. The biotech, Vilya, starts life with a $50 million, Arch-led series A round and technology to design a new class of medicines.

Scientists have discovered a new druggable pathway that may boost beta amyloid clearance, holding the potential to be used to help prevent Alzheimer’s dementia in humans.

Novo Nordisk’s recent growth renaissance has flourished thanks in no small part to semaglutide—the GLP-1 molecule behind the company’s leading trio of Ozempic, Rybelsus and Wegovy. But even as the drug's metabolic empire prospers, Novo Nordisk isn’t letting its GLP-1 rest on its laurels.

A federal appellate court ruled it doesn't have the authority to get OSHA to make permanent a COVID-19 emergency protection standard.

Alongside Teva, Amneal Pharmaceutical, Purdue subsidiary Rhodes Pharmaceuticals and Novartis’ soon-to-be-spun-off generics unit Sandoz have generic extended-released Adderall on back order, according to a recent supply update from the American Society of Health-System Pharmacists, which tracks drug shortages.

Nearly a decade after reeling in the first FDA nod allowing its deep brain stimulation technology to help treat major depressive disorder, BrainsWay has doubled back with another agency-cleared depression treatment.

SaNOtize has raised a $24 million series B round, giving it the cash to fund its ongoing phase 3 COVID-19 prevention trial and other research into its nitric oxide nasal spray (NONS).

InterWell Health completed a three-way merger with Fresenius Health Partners and Cricket Health to create a kidney care powerhouse on track to have $11 billion in costs under management by 2025. 

The FDA could authorize variant-targeted mRNA vaccines from Pfizer and Moderna as early as Wednesday, Politico first reported, citing three people close to the decision.

Folx Heath is a virtual care provider designed by and for the LGBTQ+ community, so the rise in monkeypox cases and the effect if was having on the community, spurred the company to act. Folx knew it needed to get in front of the issue, which was mired in confusion, as a source of solid health information and solutions.

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella.

Set a solid foundation for successful scale-up of buffer preparation.

The total immersion, transformative training will take place at the Harvard Club in Boston. VIRTUAL in real time is also available. Contingencies for COVID19 will apply. Register NOW for a large early bird discount www.drugstomarket.com/drugbootcamp.

See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead.

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry.

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.